Eight months after he stopped taking naltrexone, in April 2023, his primary care doctor prescribed him Wegovy, a brand name for semaglutide (the same active ingredient in Ozempic), which is FDA-approved for chronic weight management
By possibly lowering the risk of major cardiovascular events and improving outcomes through reduced blood pressure and inflammation, semaglutide aligns with our goal of comprehensive patient care, addressing both immediate and long-term health concerns
As the market expands, it is essential to ensure that convenience does not overshadow the need for patient engagement, proper use, and safety awareness
For instance, clinical trials revealed that 1.6% of patients on semaglutide developed gallstones, compared to 0.7% of those on a placebo